A new tissue-free circulating tumor DNA (ctDNA) assay identifies molecular residual disease in early triple-negative breast cancer without requiring primary tumor sequencing. Published in JAMA Oncology and highlighted in the c-TRAK TN study, the blood-based test detected recurrence risks months before clinical relapse, offering a viable alternative when tissue is unavailable.
In Plain English: The Clinical Takeaway
- What was tested: A blood test that looks for cancer-associated DNA methylation patterns without needing a sample of the original tumor.
- Why it matters: It spotted microscopic leftover cancer cells—known as molecular residual disease (MRD)—a median of 7.9 months before clinical relapse.
- Current limitation: While the test successfully flags high-risk patients, clinical utility—proving that treating at the moment of ctDNA detection improves survival—remains under investigation.
Decoding Molecular Residual Disease in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a subtype of breast cancer. Following curative-intent treatment, standard imaging and clinical assessments often show no evidence of disease. Yet, microscopic cancer can persist undetected in the body.
This persistent microscopic burden is defined as molecular residual disease, or MRD. Clinicians have used tumor-informed liquid biopsies to track MRD. These assays require sequencing the patient’s original tumor tissue first to build a personalized assay designed to search for specific genomic variants in plasma, creating logistical bottlenecks when archival tissue is missing, unavailable, or contains insufficient cancer cells.
How the Tissue-Free Assay Bypass Tumor Sequencing Barriers
To overcome these hurdles, investigators evaluated 1,026 plasma samples from 159 patients with moderate- to high-risk triple-negative breast cancer enrolled in the c-TRAK TN study. Instead of tracking patient-specific mutations derived from a tissue sample, the tissue-free Guardant Reveal assay detects cancer-associated DNA methylation patterns directly within circulating cell-free DNA.
The prognostic analysis revealed that the assay detected ctDNA in 34.0% of patients following primary treatment. Detection was strongly associated with subsequent recurrence, yielding a hazard ratio (HR) of 27.2 (95% CI, 13.7–54.2; P < .001). For individuals with a positive result, molecular detection preceded clinical relapse by a median interval of 7.9 months (Cunningham et al., 2026).
| Metric | Clinical Outcome / Value |
|---|---|
| Patient Cohort Size | 159 patients with moderate- to high-risk early TNBC |
| Plasma Samples Analyzed | 1,026 samples collected every 3 months for up to 2 years |
| ctDNA Positive Rate | 34.0% of evaluated patients |
| Recurrence Association | HR 27.2 (95% CI, 13.7–54.2; P < .001) |
| Median Lead Time | 7.9 months before clinical relapse |
Liquid biopsy surveillance is being studied in oncology workflows. Assays such as Guardant Reveal and Signatera are studied in clinical trials like I-SPY2 to gauge early therapeutic responses.
Contraindications & When to Consult a Doctor
Patients with early-stage triple-negative breast cancer undergoing post-treatment surveillance should understand the limits of ctDNA testing. Patients should never use a negative MRD ctDNA finding as justification to forego therapies or discontinue them ahead of the suggested schedule.
The Path Forward for Precision Oncology
The validation of tissue-free ctDNA surveillance marks a practical step forward in oncology, offering a scalable tool when tumor tissue is inaccessible. As prospective clinical trials continue to evaluate how oncologists can act on these early molecular warnings, liquid biopsies are poised to shift cancer care.
References
- Cunningham, et al. (2026). Prognostic Analysis of Tissue-Free ctDNA in Early Triple-Negative Breast Cancer. JAMA Oncology.
- Garcia-Murillas, I., et al. (2015). Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine.
- Garcia-Murillas, I., et al. (2019). Assessment of Plasma Circulating Tumor DNA Surveillance for Early Detection of Recurrence in Breast Cancer. JAMA Oncology.
